Evotec, Nyxoah, BioNTech – Stocks for the future?

Evotec – Waiting for the quarterly figures

Evotec faces significant challenges as investor confidence has been severely shaken. The long-standing CEO Werner Lanthaler's resignation after delayed reporting of insider transactions has thrown the Company into turmoil. In addition, the departure of Dr. Matthias Evers, Chief Business Officer, is causing further concern among investors. Such personnel changes indicate far-reaching restructuring. Amidst this environment, the shares are on a downward spiral, and investors are waiting for November 6. On this day, the Company is set to present its quarterly figures. Analysts are expecting a loss of EUR 0.075 per share.

Despite its challenging situation, Evotec is focusing on strategic partnerships as a growth strategy. A promising collaboration has been established with insulin manufacturer Novo Nordisk to work on innovative cell therapies jointly. This collaboration could be crucial to underpin Evotec's scientific expertise and create access to new markets. In addition, Evotec is working with X-Chem to strengthen its early-stage drug discovery. Such alliances offer the potential for significant milestone and license payments, although specific financial details are still lacking.

With the opening of the new J.POD® facility in Toulouse, Evotec is taking a significant step into the future. This state-of-the-art factory is designed to make biologics production more efficient and is considered the most important milestone for the Company. However, analysts remain cautious. Opinions are divided, as achieving the annual targets is linked to a better-than-expected fourth quarter. It remains to be seen whether the factory will have a positive impact on Evotec's financial recovery. The next quarterly figures could provide further information. The share price has formed a double bottom at EUR 5.20 and is currently trading at EUR 5.805.

Nyxoah – An innovative approach for the treatment of obstructive sleep apnea

Nyxoah is an innovative medical technology company specializing in the development of groundbreaking technologies for the treatment of obstructive sleep apnea (OSA). The main product, Genio®, is a lead- and battery-free hypoglossal neurostimulation system implanted under the chin in a minimally invasive procedure and activated by an external wearable. This technology promises significant relief for millions of sufferers worldwide. Additionally, the study results to date show that Genio® significantly improves patients' quality of life.

The DREAM study of Nyxoah, which is a key element of the company's US approval strategy, has delivered promising results in Spring 2024. A presentation at the Miami International Surgical Sleep Society conference in September 2024 additionally revealed clinically significant improvements in the apnea-hypopnea index (AHI) and quality of life for patients.
Based on the DREAM study the company has completed and submitted the fourth module of its application for approval to the FDA. The approval is expected by the end of 2024 and market launch is planned for the first quarter 2025. The positive response from the research community strengthens Nyxoah's position and offers hope for the many patients suffering from obstructive sleep apnea.

Analysts are optimistic about Nyxoah and have raised the target price to USD 18. The impressive results from the DREAM study and the upcoming FDA approval are boosting investor interest. Although the Company is still experiencing financial losses, the inflow of funds from recent AT-the-Market-Offering further strengthens Nyxoah’s financial position and offers the company the necessary flexibility for a successful market launch in the US. An American investor secured 3 million shares for USD 27 million. At the current share price of USD 9.53, the market capitalization is around USD 327 million.

BioNTech – Suspension of a study

BioNTech recently celebrated a significant victory in the London High Court. The court ruled that two CureVac patents relating to mRNA technology, which are crucial for BioNTech's COVID-19 vaccine, are invalid. This legal victory is part of a larger international dispute between BioNTech, Pfizer and CureVac that is being played out in several countries. BioNTech and Pfizer initially filed the lawsuit in September 2022 after CureVac had previously taken legal action against BioNTech in Germany.

But after the good news, there was a setback. In the US, a Phase III study by BioNTech and OncoC4 for lung cancer therapy was temporarily halted by the FDA. The reason for this is the discovery of different results in different patient groups. BioNTech stated that an independent review indicated possible deviations in the study data. The enrollment of new patients was immediately paused. The therapy of other diseases in which the same antibody candidate is being tested remains unaffected while future steps are being considered.

Despite all this, the BioNTech pipeline is broadly positioned to fight cancer. The planned market entry of the first cancer drug in 2026 is part of a broader strategy supported by significant investments in research and development. Analysts see great potential in this diversification. In addition, BioNTech plans to expand its AI capabilities further to advance personalized medicine. This strategy could strengthen the Company's competitive position in the long term and increase opportunities for investors. The suspension of the study has stopped the share price from soaring and caused an initial correction. The share price fell by 5.58% in Xetra trading and closed at EUR 101.50.

All three companies presented have the potential to become a pearl in the portfolio. Evotec relies on strategic partnerships with Novo Nordisk and X-Chem to strengthen its scientific expertise. Nyxoah has great potential in the area of sleep apnea treatment due to the positive DREAM study and the pursuit of FDA approval. Despite a study that was temporarily stopped, BioNTech has a diversified pipeline, particularly in the area of mRNA technology and oncology.